Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the abnormal cells.
PURPOSE: This clinical trial is studying the side effects and how well bortezomib works in
treating patients with advanced myeloproliferative disorders.